奥比帕利联合达塞布韦治疗基因1b型慢性丙型肝炎患者疗效研究  

Virological response of patients with genotype 1b infected chronic hepatitis C to combination of ombitasvir and dasabuvir antiviral therapy

作　　者：李兴泉[1] 杨春[2] 李诗源 翁凯 彭麟 Li Xingquan;Yang Chun;Li Shiyuan(Department of Infectious Diseases,District People's Hospital,Qijiang 404100,Chongqing,China;不详)

机构地区：[1]重庆市綦江区人民医院感染病科,404100 [2]重庆医科大学附属第一医院感染病科

出　　处：《实用肝脏病杂志》2024年第2期177-180,共4页Journal of Practical Hepatology

基　　金：重庆市卫生健康委员会科研基金资助项目(编号:2021HG010231)。

摘　　要：目的探讨应用奥比帕利联合达塞布韦治疗基因1b型慢性丙型肝炎(CHC)患者的疗效。方法2020年1月~2022年1月我院收治的106例基因1b型CHC患者,其中观察组53例接受奥比帕利联合达塞布韦治疗,对照组53例接受达塞布韦单药治疗,两组治疗持续12周。采用实时荧光定量RT-PCR法检测血清HCV RNA载量,考核超快速病毒学应答(SRVR)、快速病毒学应答(RVR)、治疗结束病毒学应答(ETVR)和随访12周时持续病毒学应答(SVR)。结果观察组SRVR、RVR、ETVR和SVR分别为88.7%、94.3%、100.0%和100.0%,显著高于对照组(67.9%、75.4%、83.0%和90.5%,P<0.05);在治疗12周结束时,观察组血清ALT和AST水平分别为(30.8±4.6)U/L和(29.7±2.4)U/L,均显著低于对照组【分别为(52.2±5.1)U/L和(48.1±3.6)U/L,P<0.05】;在治疗期间,观察组不良反应发生率为18.7%,显著高于对照组的9.4%(P<0.05)。结论应用奥比帕利联合达塞布韦治疗基因1b型CHC患者疗效确切,可有效改善肝功能,提高血清HCV RNA转阴率,且安全性尚可。Objective The aim of this study was to investigate the virological response of patients with genotype 1b infected chronic hepatitis C(CHC)to combination of ombitasvir and dasabuvir antiviral therapy.Methods A total of 106 patients with genotype 1b infected CHC were enrolled in our hospital between January 2020 and January 2022,53 patients in the observation group were treated with ombitasvir and dasabuvir combination and other 53 patients in the control group were treated with dasabuvir alone.The antiviral regimen lasted for 12 weeks in the two groups.Serum HCV RNA load was detected by real-time fluorescence quantitative PCR,and the super rapid virological response(SRVR),rapid virological response(RVR),end of treatment virological response(ETVR)and sustained virological response(SVR)were recorded.Results The SRVR,RVR,ETVR and SVR in the observation group were 88.7%,94.3%,100.0%and 100.0%,all significantly higher than 67.9%,75.4%,83.0%and 90.5%(P<0.05)in the control;at the end of 12 week treatment,serum ALT and AST levels in the observation group were(30.8±4.6)U/L and(29.7±2.4)U/L,both significantly lower than[(52.2±5.1)U/L and(48.1±3.6)U/L,respectively,P<0.05]in the control group;during the period of antiviral treatment,the incidence of untoward effects in the observation group was 18.7%,much higher than 9.4%(P<0.05)in the control group.Conclusion The combination of ombitasvir and dasabuvir in the treatment of patients with genotype 1b infected CHC is efficacious,with high virological response and improved liver function tests and relatively good safety.

关 键 词：慢性丙型肝炎 HCV基因1b型 奥比他韦 帕立瑞韦 利托那韦 达塞布韦 病毒学应答 治疗 

分 类 号：R512.63[医药卫生—内科学]